BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.5%

Neg 0% Neu 88.5% Pos 0%

BTIG analyst Ryan Zimmerman reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $2 price target.

Comments

No comments yet. Be the first!